The Asian Scientist 100
Di Li
Institution
National Astronomical Observatories of the Chinese Academy of Sciences
Country
China
Field
Aerospace & Astronomy
Li received the Marcel Grossmann Award for his pioneering contributions in the field of fast radio bursts. Li is the first scientist in China to receive this prize for research conducted within China.
(Photo: The Paper)
AWARDS
- Marcel Grossmann Award
Related articles
Royal Society President Sir Paul Nurse Visits Chinese Academy Of Sciences
President of the Royal Society Sir Paul Nurse gave a lecture at the University of the Chinese Academy of Sciences during his first official visit to China.
GE Healthcare Life Sciences To Build Biopharma Factory In China
GE Healthcare Life Sciences and biologics manufacturer JHL Biotech today announced that they will build a new biopharmaceutical factory in China.
Obesity Gene Affects Hip Fracture Risk
Australian researchers have demonstrated a strong association between the FTO (fat and obesity) gene and hip fracture in women.
French Horn Players Prone To Hearing Loss
A study has found that French horn players have among the highest risk of developing hearing loss among professional orchestral musicians.
‘Raspberry Particles’ As Sticky Tape For Water Droplets
Scientists have assembled rose petal-inspired 'raspberry particles' that act like sticky tape for water droplets.
Immune Cells Have A Role In Breast Cancer
A study by researchers in Australia has highlighted the important role played by immune cells in the risk of developing breast cancer.
Predictive Test For Obesity In Human Trials
Scientists in Australia are recruiting subjects for a trial to test if the stress hormone cortisol is a predictor of obesity.
Luqa Pharma, Stratpharma Extend Collaboration In China
Stratpharma and Luqa Pharma have extended their collaboration past 2020 in the areas of cosmetic dermatology, plastic surgery, burns, wounds and scar management.
MicroConstants China Licenses Liver Cancer Drug From Pertinax Therapeutics
MicroConstants China Inc. has licensed the China rights for a Phase II liver cancer drug candidate, PTX-9908, from Pertinax Therapeutics of Canada.